Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Which antifungal agent for onychomycosis? A pharmacoeconomic analysis
Autore:
Joish, VN; Armstrong, EP;
Indirizzi:
Univ Arizona, Coll Pharm, Dept Pharmaceut Sci, Tucson, AZ 85721 USA Univ Arizona Tucson AZ USA 85721 ept Pharmaceut Sci, Tucson, AZ 85721 USA Univ Arizona, Coll Pharm, Dept Pharm Practice & Sci, Tucson, AZ 85721 USA Univ Arizona Tucson AZ USA 85721 arm Practice & Sci, Tucson, AZ 85721 USA
Titolo Testata:
PHARMACOECONOMICS
fascicolo: 10, volume: 19, anno: 2001,
pagine: 983 - 1002
SICI:
1170-7690(2001)19:10<983:WAAFOA>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
QUALITY-OF-LIFE; COST-EFFECTIVENESS ANALYSIS; TOENAIL ONYCHOMYCOSIS; DOUBLE-BLIND; DERMATOPHYTE ONYCHOMYCOSIS; INTERMITTENT ITRACONAZOLE; MULTICENTER SURVEY; TOPICAL TREATMENT; ORAL THERAPIES; TERBINAFINE;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
90
Recensione:
Indirizzi per estratti:
Indirizzo: Joish, VN Univ Arizona, Coll Pharm, Dept Pharmaceut Sci, Tucson, AZ 85721 USA Univ Arizona Tucson AZ USA 85721 ceut Sci, Tucson, AZ 85721 USA
Citazione:
V.N. Joish e E.P. Armstrong, "Which antifungal agent for onychomycosis? A pharmacoeconomic analysis", PHARMACOECO, 19(10), 2001, pp. 983-1002

Abstract

The incidence of fungal nail infections is increasing and this is possiblybecause of several factors: better methods of detection, a growing population of immunocompromised patients who have a greater susceptibility to suchinfections, the increased use of immunosuppressive drugs, the increasing number of elderly people, worldwide travel, and the use of communal bathing facilities. Onychomycosis is a fungal infection of the fingernails and toenails that accounts for about 30% of all superficial fungal infections. It is characterised by nail discoloration, thickening and ultimately destruction of the nail plate. Management of this disease has improved significantly and treatment patterns have dramatically changed in recent years as a result of advances in new treatment options (e.g. oral antifungal agents) and changes in treatment regimens (e.g. pulse therapy). Also, newer drugs for onychomycosis have improved tolerability profiles compared with older agents. The overall costs of treating onychomycosis are substantial, and it has been estimated that direct cost for US Medicare patients with the disease is $US43 million per year (year of costing not available). Pharmacoeconomic studies help in the decision-making process when selecting the most cost-effective antifungal agents to treat onychomycosis. To datethere have been a number of national and international economic studies aimed at effectively assessing the efficacy and costs of the treatment options available to cure onychomycosis. The objectives of this paper are to (i) review the published findings regarding the epidemiology of onychomycosis (ii) summarise the original pharmacoeconomic studies that describe the economic impact of the disease; and (iii) address the impact of the disease on patients' health-related quality of life.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/21 alle ore 04:43:51